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to the editoR
Revertant mosaicism (RM) is the coexistence of mutant cells carrying germline mutations and 
revertant cells that have spontaneously corrected the germline mutation by a somatic reverse 
mutation. Revertant mosaicism has been reported for a number of genetic diseases,1 including 
epidermolysis bullosa. Moreover, the first case of revertant mosaicism in skin was found in a 
Dutch patient 026-01 with junctional epidermolysis bullosa caused by mutations in COL17A1. 
The patient was compound heterozygous for a maternal deletion in exon 18, c.1601delA, and 
paternal nonsense mutation in exon 51, c.3676C>T.2 Due to gene conversion the c.1601delA 
mutation was corrected and the patient presented a clinically healthy skin patch on her forearm 
(Figure 1a), where affected (mutant) and corrected (revertant) keratinocytes co-existed (Fig-
ure 1b). Recently, we found revertant mosaicism to occur in all Dutch patients with junctional 
epidermolysis bullosa.3,4
Naturally corrected keratinocytes expressing type XVII collagen (Col17) harvested from a revert-
ant patch can be used for autologous cell therapy. Unfortunately, the first attempt to transplant 
revertant keratinocytes did not succeed because of a surprisingly low percentage of revertant 
cells in the graft (3%).5 To explain the depletion of revertant cells we have analyzed the process 
of skin equivalent production. Additionally, we have decided to study the feasibility of revertant 
cell therapy in an animal model to assess the long-term survival of revertant cells after engraft-
ment. Written, informed consent was obtained, and all procedures were conducted in accor-
dance with the Declaration of Helsinki principles.
Our revertant cell source was the revertant patch on the forearm of patient 026-01 (Figure 1a). 
A previous biopsy specimen from this area stained for Col17 showed 50% revertant cells (Figure 
1b).2,4,6 Next to the earlier diagnostic biopsy location a 6-mm punch biopsy was taken (Figure 
1c) from which keratinocytes and fibroblasts were isolated with collagenase and trypsine/EDTA 
enzymatic digestion, and cultured as described before.7 Keratinocytes were cultured on a feeder 
layer and passaged when confluent to expand the culture for animal model experiments and 
banking. The first passage was performed 9 days after isolation and the second passage (p2) 
was done 7 days later. During both passages a side sample was taken, cultured on coverslips, 
airfixed and the number of revertant cells was assessed by immunofluorescence (IF) microscopy 
with the 1A8C monoclonal antibody (mAb) against Col17 (gift from Dr. K. Owaribe, Nagoya, Ja-
pan). Stainings showed 40% revertant cells after first passage, and 25% revertant cells after the 
second passage (Figure 1e and 1i). A sample of the keratinocytes was further cultured, which led 
to a drop of revertant cells to 15%, 1% and <1% after passage 3, 4 and 5, respectively. Growth 
potential was tested with colony forming efficiency assay and showed that cells isolated from 
the revertant patch had growth potential comparable to keratinocytes from a healthy patient 
(Supplementary 1). Colonies were further stained with VK4 mAb, which revealed that colony 
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forming potential was higher in revertant cells (39% of colonies were revertant compared with 
15% of revertant cells in the population used for the assay), but their division rate represented 
by colony size, was lower (Figure 1d).
From cultured patient’s fibroblasts and p2 keratinocytes, a 75cm2 bioengineered skin equiva-
lent was produced as described before.7,8 Briefly, a plasma-based scaffold filled with fibroblasts 
was used as a dermal component of the bioengineered revertant skin: 7.5x104 cultured fibro-
blasts were resuspended in 10 mL of donor plasma (obtained form the blood bank), 10 mg of 
tranexamic acid (Amchafibrin, Rotapharm, Barcelona, Spain), 2 mL of CaCl2 1% and adjusted 
to 25 mL by adding NaCl 0.9%. The mixture was placed in a 75 cm2 tissue culture flask and 
allowed to solidify at 37°C for 30 minutes. Once the dermal equivalent solidified, it was covered 
with culture medium and 24 h later cultured keratinocytes were seeded. After 8 days, when 
keratinocytes reached confluence, the skin equivalent was harvested and moved to the animal 
facility. The equivalent was then divided into four pieces, 9cm2 each, for grafting and samples 
were frozen for the Col17 immunofluorescence analysis. The sample sections were stained with 
1A8C mAb against Col17 and analysed by measurement of Col17 positive fragments. This anal-
ysis revealed that 20% of the graft consisted of revertant cells (Figure 1f). 
Four immunodeficient nu/nu mice were transplanted as described before.8,9 Biopsies from 
the engrafted skin (Figure 1g) were taken after 10 and 16 weeks and directly frozen in liquid 
nitrogen. Each of the four biopsies was cut into 4-µm sections and stained with 1A8C or VK4 
mAb (dr. H. H. Pas, Groningen, the Netherlands)10 against Col17 to assess revertant cell sur-
vival, and with mAb (AF109) specific for murine keratin 1 (Prof. D. Roop, Denver, U.S.A.)11 to 
distinguish human and murine epidermis. Once again, length of Col17 positive fragments and 
the total length was measured and analysis revealed that revertant cells were present in 20% 
of the human epidermis after both time points (Figure 1h and 1i). This corresponded with the 
percentage of revertant cells found in the skin equivalent and suggested a long-term survival of 
Col17 producing cells. To prove that the reversion mechanism was present in the areas positive 
for Col17, laser dissection microscopy (LDM) followed by nested PCR were performed on all 
biopsies as described earlier.6 In fragments of human epidermis positive for Col17 we found the 
same postzygotic reversion mutation as in donor site keratinocytes on the patient’s forearm, i.e. 
the loss by gene conversion of the maternal COL17A1: c.1601delA mutation.
The reason for a decreased percentage of revertant cells remains unknown. It has been shown 
that Col17 influences hair follicle stem cells in mice and that cells lacking Col17 have a different 
phenotype in-vitro.12 Furthermore, Col17 deficiency activates a pro-inflammatory pathway by 
up-regulation of NF-κB, whereas in healthy keratinocytes that express Col17, levels of NF- κB 
are low.13 Therefore, the growth advantage in cultures of Col17-negative keratinocytes over 
Col17-positive keratinocytes might be explained by NF-κB activation that stimulates epidermal 
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proliferation in the Col17 negative cells.14 Further studies are required to assess whether such 
differences account for a growth advantage of mutant keratinocytes. To overcome the in-vitro 
depletion of revertant cells for a therapeutic approach, a method for selection of Col17 revertant 
cells compatible with clinical patient care is needed. 
In this study we show that after a marked decrease during in-vitro expansion on plastic, the 
percentage of revertant keratinocytes stabilizes during skin equivalent production and remains 
stable in-vivo (Figure 1i). This proves long-term survival of revertant keratinocytes suggesting 
that we transplanted revertant epidermal stem cells. Hereby we demonstrate the feasibility of 
the revertant cell therapy for Col17 deficient patients. 
Figure 1 (right). (a) Patient 026-01: left arm, outlined revertant patches, red asterisk marks the location of previous diagnos-
tic biopsy; (b) Immunofluorescence of the diagnostic biopsy showing 50 % of the cells being reverant (white asterisk); (c) 
Biopsy for cell culture is taken from the revertant patch (outlined) next to the previous diagnostic biopsy (red asterisk); (d) 
Immunohistochemical staining of the colony forming efficiency assay with VK4 mAb showing two small revertant colonies 
(red asterisk) next to a large mutant colony (black asterisk); (e) Cultured keratinocytes on coverslips stained with 1A8C mAb 
(green) against the intracellular domain of Col17. In blue cell nuclei; (f) Samples of skin equivalent stained with 1A8C mAb 
(green). In blue cell nuclei. White asterisk indicates the revertant regions of the epidermis; (g) Revertant graft (asterisk) on 
mouse back 6 weeks after transplantation. Pigmentation is visible where human skin is present; (h) Graft on mouse sampled 
10 weeks after transplantation and stained with VK4 mAb (green) against the intracellular domain of Col17 and with mAb 
against mouse keratin 1 (red). In blue cell nuclei. The white line separates murine (Mouse) and human (Human) epidermis; 
(i) Percentage of revertant cells during in-vitro culture, production of the skin equivalent and after transplantation. For in-vi-
tro analysis after passage 1 and passage 2, 4761 and 2924 cells were counted, respectively.
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supplementaRy
Colony Forming Efficiency (CFE) assay of wild type keratinocytes isolated from normal human 
skin (a) and keratinocytes isolated from the revertant patch of patient 026-01 (b). Cells were 
seeded for CFE at passage 3. Briefly, 1000 cells were seeded per 100mm dish and cultured on 
a feeder layer for 14 days, followed by fixation in 10% buffered formaldehyde and subsequent 
staining with a 1% Rhodamine B solution. Colonies larger than 2mm in diameter were counted. 
CFE values were 9,7 % ± 0,4 % and 10,4±2,6% (n=3) for wild type and patient’s keratinocytes 
respectively.
Parallel colony assays were fixed with ice-cold acetone/methanol for 10 minutes and stained 
with VK4 monoclonal antibody against type XVII collagen to visualize revertant cells. The 
total number of non-abortive colonies was 204, which consisted of 80 revertant (39%) and 
124 mutant (61%) colonies. The percentage of revertant colonies (39%) was higher than the 
percentage of revertant cells in the original population (assessed by staining of cover slips, 15%) 
suggesting higher potential of Col17-positive cells to form colonies when seeded sparse.
Mutant colonies, however, were on average bigger than revertant ones, as measured with Ado-
be Photoshop CS3 and analysed with Microsoft Excel – median size of Revertant colony was 949 
pixels (n=50) and of Mutant colony 2439 pixels (n=50). 
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